Cure8 research brief
People with IBD who’ve had organ transplants (or are concerned about infection risk from systemic immunosuppression) may be interested because vedolizumab’s gut‑selective action could be preferable after kidney transplantation.
The report describes a patient treated successfully for nearly 2.5 years without reported adverse reactions.
Patients with IBD who are organ transplant recipients or on transplant immunosuppression; gastroenterologists; transplant clinicians; patients considering biologic therapy after transplantation.
A kidney transplant recipient with underlying IgA nephropathy developed de novo ulcerative colitis after transplantation and was treated with vedolizumab. The abstract reports successful treatment with no adverse reactions over 29 months of follow-up.
This is a single-case report (abstract-level) describing use of vedolizumab, an anti‑integrin biologic, in the specific context of post‑kidney-transplant IBD.
It suggests vedolizumab may be an option because of gut-selective action that could pose less systemic immunosuppression than other agents, but a case report cannot establish safety or efficacy for broader transplant populations.
If considering applicability, clinicians would need to weigh this single-case experience against broader evidence, transplant immunosuppression regimens, infection risk, and specialist guidance. The abstract alone limits detailed assessment of concurrent immunosuppressive drugs, monitoring, or adverse-event definitions.
This is a single case report summarized from the article abstract (structured-content depth: abstract). Case reports can illustrate possibilities but cannot determine typical safety or effectiveness. The abstract gives limited detail on concurrent transplant immunosuppression or monitoring; full article review and specialist consultation are needed before changing care.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors declare no conflicts of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians...
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
